Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects

Inclusion Criteria: * Healthy male or female subjects between the ages of 18 and 55 years * Negative urine pregnancy test on Day1 for females of childbearing potential * Weight within +/- 20 percent of ideal weight according to the Metropolitan Life Height and Weight chart * Willing and able to cooperate with the investigator and his/her staff * Written informed consent in accordance with GCP (Good Clinical Practice) and local legislation Exclusion Criteria: * Any finding, medical condition or dietary restriction that, in the investigator's opinion, may interfere with optimal participation in the study or produce a significant risk to the subject * In the opinion of the investigator, the subject has any disease or condition that may result in altered absorption, excess accumulation, or impaired metabolism or excretion of the trial medications * A known or suspected hypersensitivity to any of the trial medications or their excipients or any other NSAIDs (Non-Steroid Anti-Inflammatory Drug) * A history of gastrointestinal ulcer, perforation or bleeding * A history of cerebrovascular bleeding or any other bleeding disorder * Women of childbearing potential not using adequate contraception (e.g, intrauterine device, contraceptive pills, Depo-Provera® implant, barrier device) for at least 3 months prior to, and for the duration of trial participation. It should be noted that NSAIDs may interfere with the effectiveness of intrauterine devices * History of bronchial asthma * Use of any medications that might influence the results of the trial * Use of anticoagulants, including warfarin, heparin, ticlopidine, clopidogrel or aspirin * Any laboratory value outside the normal range that is considered clinically significant by the investigator. In addition, subjects with the following specific laboratory values will not be allowed: * A serum creatinine concentration at baseline \> 1.5 mg/dl * SGOT (serum glutamic-oxaloacetic transaminase) or SGPT (serum glutamic-pyruvic transaminase) liver enzymes results at baseline \> 1.5 times the upper limit of normal * A hemoglobin concentration \< 10.5 g/dl * A white cell count \< 3500/mm³ * A platelet \< 100,000/mm³ or a documented abnormal bleeding time, platelet aggregation, thromboxane B2 synthesis, thromboplastin time (PT) or activated partial thromboplastin time (APTT) * Inability to refrain from smoking on testing days * Participation in another trial with an investigational drug within 30 days of entering the trial * Subjects with increased keloid formation * Previous surgery of the gastrointestinal tract (except appendectomy) * Participation in excessive physical activities (≤ 5 days prior to administration) * Current drug or alcohol abuse * Small or difficult to locate arm veins that would impair the clinician's ability to draw blood samples * Homeopathic medication